News

Nutriband Inc. Invites Individual and Institutional Investors As Well as Advisors and Analysts, To Attend Its Real-Time, Interactive Presentation at the Emerging Growth Conference ORLANDO, FL / ACCESSWIRE / May 20, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), is pleased to announce that it has been invited to present at the Emerging Growth Conference on May 25, 2022. This live, interactive online event will give existing shareholders …

Nutriband Inc. to Present at the Emerging Growth Conference on May 25 Read More »

ORLANDO, FL / ACCESSWIRE / May 17, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced today it has booked nearly a quarter of a million dollars in new in contract manufacturing orders through its wholly-owned subsidiary Pocono Pharma, extending its current run of record-breaking revenue. The reported amount of the orders, which is just over $234,000, exceeds the …

Nutriband Inc. Receives Orders for $230,000 in Contract Manufacturing for First 3 Weeks of May Read More »

Class 1 Medical Device Registration Allows Nutriband To Explore New Product Manufacturing Opportunities Through Its Wholly Owned Subsidiary Active Intelligence LLC ORLANDO, FL / ACCESSWIRE / May 11, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced its Active Intelligence LLC subsidiary has registered as a Class I medical device manufacturer with the …

Nutriband Subsidiary Active Intelligence LLC Registers with FDA as a Medical Device Manufacturer for its AI Kinesiology Tape Product Read More »

ORLANDO, Fla., April 29, 2022 /PRNewswire/ — Nutriband Inc. (NASDAQ: NTRB), a developer of transdermal pharmaceutical products, today announced financial and operational results for the fiscal year ended January 31, 2022. Key Highlights: Generated record revenue of $1.4 million, up 56% over the prior fiscal year Completed uplisting to Nasdaq Capital Market in October 2021 and concurrent offering that raised total gross …

Nutriband Inc. Reports Revenue Up 56% in Fiscal 2022 to a Record $1.4M Read More »

ORLANDO, Fla., Feb 16, 2022 – Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), has announced that the United States Patent and Trademark Office (USPTO) has published its patent titled “Abuse and Misuse Deterrent Transdermal System” which is related to the Company’s lead technology AVERSA™. US Patent 11,246,840 dated Feb 15, 2022 underpins 4P Therapeutics’ abuse deterrent …

Nutriband Inc.’s patent, ‘Abuse and Misuse deterrent transdermal system’ published by the United States Patent and Trademark Office following recent issuance notice Read More »

ORLANDO, Fla., January 28, 2022 – Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced the receipt of an Issue Notification from the United States Patent and Trademark Office (USPTO) for its United States patent entitled, “Abuse and Misuse Deterrent Transdermal System,”  that protects its AVERSA™ transdermal abuse deterrent technology.   Nutriband’s AVERSA™ abuse deterrent technology can be utilized …

Nutriband issued full US patent for its AVERSA™ abuse deterrent transdermal platform by United States Patent and Trademark Office. Read More »

ORLANDO, FL / ACCESSWIRE / January 18, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced an expanded product development pipeline for its proprietary AVERSA™ abuse deterrent transdermal technology. The AVERSA abuse deterrent technology platform can be applied to any transdermal patch that has a risk of abuse, misuse or accidental exposure. It is based on incorporating aversive agents …

Nutriband Inc. Expands Product Development Pipeline for Its AVERSA(TM) Platform Abuse Deterrent Technology Read More »

ORLANDO, Fla., January 10, 2022 – Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced the signing of a feasibility agreement with Kindeva Drug Delivery to develop Nutriband’s lead product, AVERSA™ Fentanyl, based on its proprietary AVERSA™ abuse deterrent transdermal technology and Kindeva’s FDA-approved transdermal fentanyl patch (fentanyl transdermal system).  The feasibility agreement is focused on adapting Kindeva’s …

Nutriband Inc. and Kindeva Drug Delivery sign feasibility agreement to develop AVERSA™ Fentanyl, an abuse deterrent fentanyl patch Read More »

ORLANDO, FL / ACCESSWIRE / January 5, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of transdermal pharmaceutical products has completed the market assessment and commercialization strategy for its lead product candidate, AVERSA™ Fentanyl, an abuse deterrent fentanyl transdermal system. The company engaged leading healthcare consulting company Health Advances to assess the market opportunity …

Nutriband Lead Product Aversa(TM) Fentanyl May Reach Peak Annual Sales of $80-200 Million Based on Market Assessment by Leading Healthcare Consulting Firm Read More »

ORLANDO, FL / ACCESSWIRE / December 31, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), has announced that the Korean Intellectual Property Office (KIPO) has fully issued its patent titled “Abuse and Misuse Deterrent Transdermal System” which is related to the Company’s lead technology AVERSA™. The patent underpins 4p Therapeutics’ abuse deterrent transdermal system, AVERSA, which uses taste aversion …

Nutriband Inc. Issued Full Patent from the Korean Intellectual Property Office for Its “Abuse and Misuse Deterrent Transdermal System” Application Read More »